加味痛泻要方联合培菲康治疗腹泻型肠易激综合征疗效观察被引量：6

下载PDF

导出

摘要目的评估应用加味痛泻要方联合双歧杆菌、嗜酸乳杆菌、肠球菌三联活菌胶囊(培菲康)治疗腹泻型肠易激综合征(IBS-D)的临床疗效起效时间及安全性。方法选取符合罗马Ⅲ诊断标准的IBS-D患者131例,将其随机分为治疗组67例和对照组64例,治疗组给予加味痛泻要方联合培菲康治疗,对照组单纯给予培菲康治疗,疗程均为8周,观察比较2组临床疗效。结果治疗组较对照组在单项症状计分及总症状计分(除外排便急迫程度计分)方面均明显下降(P均<0.05),治疗组临床治疗总有效率高于对照组(P<0.05),且治疗组起效时间明显早于对照组(P<0.05)。结论加味痛泻要方联合培菲康治疗腹泻型肠易激综合征8周疗效明确,较单一应用培菲康效果显著,无不良反应。加味痛泻要方联合培菲康治疗腹泻型肠易激综合征8周后临床疗效较治疗4周后无明显提高。

作者吴宇

机构地区北京市延庆区医院

出处《现代中西医结合杂志》 CAS 2016年第11期1198-1200,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine

关键词腹泻型肠易激综合征加味痛泻要方双歧杆菌、嗜酸乳杆菌、肠球菌三联活菌胶囊

分类号 R574 [医药卫生—消化系统]

引文网络
相关文献

参考文献8

1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
2吴兵,张声生.肠易激综合征腹泻型的证候学研究进展[J].北京中医,2007,26(5):312-314. 被引量：64
3Moayyedi P,Ford AC,Tallery NJ,et al.The efficacy of probiotics in the treatment of irritable bowel syndrome:a systematic review[J].Gut,2010,59(3):325-332.
4王子恺,杨云生.肠道微生物与肠易激综合征[J].中华内科杂志,2013,52(3):245-247. 被引量：29
5国家中医药管理局.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002.99-104.
6Ford AC,Spiegel BM,Talley NJ,et al.Small intestinal bacterial overgrowth in irriable bowel syndrome:systematic review and meta-analysis[M].Clin Gastroenterol Hepatol,2009,7(12):1279-1286.
7Pimentel M,Constantino T,Kong Y,et al.A 14-day elemental diet is highly effective in normalizing the lactulose breath test[J].Dig Dis Sci,2004,49(1):73-77.
8Pimentel M,Lembo A,Chey WD,et al.Rifaximin therapy for patients with irritable bowel syndrome without constipation[J].N Engl J Med,2011,364(1):22-32.

二级参考文献34

1周军丽,张颖.辨证治疗肠易激综合征疗效观察[J].山西中医,2005,21(2):16-17. 被引量：10
2彭林.辨证分型治疗泄泻型肠易激综合征58例[J].江西中医药,2005,36(6):27-28. 被引量：13
3Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology, 2006,130 : 1480-1491.
4Abrams GD, Bishop JE. Effect of the normal microbial flora on gastrointestinal motility. Proc Soe Exp Biol Med, 1967,126 : 301- 304.
5Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology,2011,141 : 1782-1791.
6Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil, 2010,22 : 512- 519. el 14-5.
7Makhani M, Yang J, Mirocha J, et al. Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. J Clin Gastroenterol,2011,45 :40-44.
8Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology, 2009,136 : 1979-1988.
9Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol,2009,7 : 1279-1286.
10Moayyedi P, Ford AC, Talley N J, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut ,2010,59:325-332.